Olmesartan/hydrochlorothiazide

Olmesartan/hydrochlorothiazide
Combination of
HydrochlorothiazideThiazide diuretic
OlmesartanAngiotension receptor blocker
Names
Trade namesBenicar HCT, Benitec H, others
Clinical data
WHO AWaReUnlinkedWikibase error: ⧼unlinkedwikibase-error-statements-entity-not-set⧽
Routes of
use		By mouth
Defined daily dosenot established[1]
Legal
Legal status
  • In general: ℞ (Prescription only)

Olmesartan/hydrochlorothiazide, sold under the brand name Benicar HCT among others, is a medication used to treat high blood pressure.[2] It is a combination of olmesartan, an angiotension receptor blocker and hydrochlorothiazide, a diuretic.[2] It may be used if olmesartan is not sufficient to manage blood pressure.[3] It is taken by mouth.[3]

Common side effects include nausea, dizziness, and upper respiratory tract infections.[4] Serious side effects may include kidney problems, allergic reactions, electrolyte problems and low blood pressure.[4] Use in pregnancy is not recommended.[4] Olmesartan works by blocking the effects of angiotensin II while hydrochlorothiazide works by increasing the loss of sodium by the kidneys.[4]

No generic version is available in the United States as of 2017.[2] A month supply in the United Kingdom costs the NHS about 13 £ as of 2019.[3] In the United States the wholesale cost of this amount is about US$6.[5] In 2017, it was the 292nd most commonly prescribed medication in the United States, with more than one million prescriptions.[6][7]

Dosage

The defined daily dose is not established[1]

Society and culture

Cost

A month supply in the United Kingdom costs the NHS about 13 £ as of 2019.[3] In the United States the wholesale cost of this amount is about US$6.[5] In 2017, it was the 292nd most commonly prescribed medication in the United States, with more than one million prescriptions.[6][7]

  • Olmesartan/hydrochlorothiazide costs (US)
    Olmesartan/hydrochlorothiazide costs (US)
  • Olmesartan/hydrochlorothiazide prescriptions (US)
    Olmesartan/hydrochlorothiazide prescriptions (US)

References

  1. 1 2 "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 1 July 2021. Retrieved 10 September 2020.
  2. 1 2 3 Bope, Edward T.; Kellerman, Rick D. (2016). Conn's Current Therapy 2017 E-Book. Elsevier Health Sciences. p. 124. ISBN 9780323443357. Archived from the original on 2019-12-19. Retrieved 2019-03-10.
  3. 1 2 3 4 British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 177–178. ISBN 9780857113382.
  4. 1 2 3 4 "Olmesartan Medoxomil and Hydrochlorothiazide - FDA prescribing information, side effects and uses". Drugs.com. Archived from the original on 18 December 2019. Retrieved 11 March 2019.
  5. 1 2 "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Archived from the original on 2019-03-06. Retrieved 3 March 2019.
  6. 1 2 "The Top 300 of 2020". ClinCalc. Archived from the original on 12 February 2021. Retrieved 11 April 2020.
  7. 1 2 "Hydrochlorothiazide; Olmesartan Medoxomil - Drug Usage Statistics". ClinCalc. Archived from the original on 26 September 2020. Retrieved 11 April 2020.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.